Endomorphin-1

Endomorphin-1 (EM-1, Tyr-Pro-Trp-Phe-NH₂) is an endogenous tetrapeptide discovered in 1997 by Zadina and colleagues in bovine and human brain tissue. It possesses the highest affinity and selectivity for the mu-opioid receptor (MOR) of any known endogenous opioid peptide, with approximately 4,000-fold selectivity over delta and 15,000-fold selectivity over kappa opioid receptors.

Overview

The discovery of endomorphin-1 and its companion peptide endomorphin-2 by Zadina et al. (1997) addressed a longstanding question in opioid pharmacology: what are the endogenous ligands for the mu-opioid receptor? While beta-endorphin, met-enkephalin, and leu-enkephalin had been identified as endogenous opioids decades earlier, none displayed the high mu-selectivity that the receptor's pharmacological profile implied (Zadina et al., 1997).

Endomorphin-1 is distributed primarily in supraspinal regions associated with pain processing, including the periaqueductal gray, thalamus, amygdala, nucleus accumbens, and cortex. This distribution pattern distinguishes it from endomorphin-2, which is more concentrated in the spinal cord dorsal horn. The supraspinal localization of EM-1 suggests it plays a primary role in descending pain inhibition and the affective-motivational dimension of pain.

Despite its discovery nearly three decades ago, the gene encoding endomorphin-1 has not been definitively identified, and its biosynthetic pathway remains uncertain. This has led to debate about whether endomorphins are true gene products or are generated through non-ribosomal peptide synthesis or enzymatic processing of larger precursors.

Mechanism of Action

Endomorphin-1 produces its effects through highly selective mu-opioid receptor activation:

• Mu-opioid receptor binding: EM-1 binds MOR with Ki ~0.36 nM, comparable to DAMGO (the reference mu-agonist) but with vastly superior selectivity. The Trp³ residue is critical for mu-selectivity, as replacement with Phe (yielding EM-2) modestly reduces affinity and alters the mu/delta selectivity ratio (Zadina et al., 1997).
• Gi/Go-coupled signaling: MOR activation inhibits adenylyl cyclase, opens G protein-coupled inward-rectifying potassium channels (GIRKs, producing neuronal hyperpolarization), and closes voltage-gated calcium channels (reducing neurotransmitter release). These mechanisms underlie both supraspinal and spinal analgesia.
• Supraspinal analgesia: Intracerebroventricular (ICV) EM-1 produces potent dose-dependent analgesia in hot-plate and tail-flick tests, primarily through activation of descending inhibitory pathways from the periaqueductal gray to the rostral ventromedial medulla (Ohsawa et al., 2001).
• Reduced respiratory depression: Several studies suggest EM-1 produces less respiratory depression relative to its analgesic effect compared to morphine, though this finding is not universal and may depend on route and dose. The mechanism may involve biased agonism — preferential activation of G protein signaling over beta-arrestin recruitment (Czapla et al., 2000).
• Reduced tolerance development: Some preclinical studies indicate that chronic EM-1 administration produces less tolerance than morphine, potentially related to different patterns of receptor internalization and recycling.

Reconstitution Calculator

Research

Safety Profile

Endomorphin-1 is an endogenous peptide and is not used clinically. Preclinical safety data from research administration include:

• Analgesia with reduced respiratory depression: At equianalgesic doses, EM-1 produces less respiratory depression than morphine in most (but not all) studies
• Reduced constipation: Some evidence of less GI motility inhibition compared to morphine at equianalgesic doses
• Hemodynamic effects: EM-1 can cause hypotension and bradycardia at high doses via MOR-mediated mechanisms
• Tolerance: Develops with repeated administration but may be less rapid than with morphine
• Physical dependence: Reported with chronic ICV administration, producing naloxone-precipitated withdrawal signs
• Rapid degradation: The extremely short plasma half-life of native EM-1 effectively limits systemic side effect duration but also limits therapeutic utility

Pharmacokinetic Profile